PTH and osteonecrosis: However, while treatment with LLP2A-Alendronate (a bone targeted agent that guides endogenous or exogenous mesenchymal stromal cells to bone) or parathyroid hormone (PTH) increased CD31 and endomucin cells similar to vehicle group, no change in prevalence of osteonecrosis was noted 86.